You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,981,618


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,981,618
Title:Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
Inventor(s): Yu; Dihua (Houston, TX), Zhou; Xiaoyan (Shanghai, CN), Nagata; Yoichi (Tosu, JP), Esteva; Francisco J. (Bellaire, TX), Sahin; Aysegul A. (Houston, TX)
Assignee: Board of Regents of The University of Texas System (Austin, TX)
Application Number:10/983,011
Patent Claims:1. A method of determining whether a patient has a lower probability of response to treatment comprising an ErbB2-targeting anti-cancer agent, the method comprising: determining the PTEN status of a sample obtained from said patient and correlating PTEN negative or PTEN low to a lower probability of response to said treatment.

2. The method of claim 1, wherein determining the PTEN status of a sample obtained from said patient comprises immunochemical analysis of PTEN protein expression level in said sample.

3. The method of claim 2, wherein said sample is contacted with an anti-PTEN monoclonal antibody.

4. The method of claim 3, wherein said sample is assigned a PTEN negative or PTEN low status if the PTEN protein expression level in said sample is below normal.

5. The method of claim 4, wherein said ErbB2-targeting anti-cancer agent is trastuzumab.

6. The method of claim 1, wherein said patient's cancer overexpresses ErbB2.

7. The method of claim 1, further comprising determining ErbB2 status in a sample obtained from said patient.

Details for Patent 7,981,618

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2023-11-05
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2023-11-05
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2023-11-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.